165 lines
49 KiB
Text
165 lines
49 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK24582">
|
|
<meta name="ncbi_domain" content="micad">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK24582/?report=reader">
|
|
<meta name="ncbi_pagename" content="99mTc-Mercaptoacetyl-Glu-Glu-Glu-Affibody ZHER2:342 - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>99mTc-Mercaptoacetyl-Glu-Glu-Glu-Affibody ZHER2:342 - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/micad/TcTTA1/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/micad/Z-MAG3-99mTc/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/micad/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Molecular Imaging and Contrast Agent Database (MICAD) [Internet]">
|
|
<meta name="citation_title" content="99mTc-Mercaptoacetyl-Glu-Glu-Glu-Affibody ZHER2:342">
|
|
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="citation_date" content="2008/04/07">
|
|
<meta name="citation_author" content="Kam Leung">
|
|
<meta name="citation_pmid" content="20641930">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK24582/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="99mTc-Mercaptoacetyl-Glu-Glu-Glu-Affibody ZHER2:342">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="DC.Contributor" content="Kam Leung">
|
|
<meta name="DC.Date" content="2008/04/07">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK24582/">
|
|
<meta name="description" content="Epidermal growth factor (EGF) is a cytokine that comprises 53 amino acids (6.2 kDa) and is secreted by ectodermic cells, monocytes, kidneys, and duodenal glands (1). EGF stimulates growth of epidermal and epithelial cells. EGF and at least seven other growth factors and their transmembrane receptor kinases play important roles in cell proliferation, survival, adhesion, migration, and differentiation. The EGF receptor (EGFR) family consists of four transmembrane receptors: EGFR (HER1/erbB-1), HER2 (erbB-2/neu), HER3 (erbB-3), and HER4 (erbB-4) (2). HER1, HER3, and HER4 comprise three major functional domains: an extracellular ligand-binding domain, a hydrophobic transmembrane domain, and a cytoplasmic tyrosine kinase domain. No ligand has been clearly identified for HER2. However, HER2 can be activated as a result of ligand binding to other HER receptors with the formation of receptor homodimers and/or heterodimers (3). HER1 and HER2 are overexpressed on many solid tumor cells such as breast, non-small cell lung, head and neck, and colon cancers (4-6). The high levels of HER1 and HER2 expression on cancer cells are associated with a poor prognosis (7-10).">
|
|
<meta name="og:title" content="99mTc-Mercaptoacetyl-Glu-Glu-Glu-Affibody ZHER2:342">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Epidermal growth factor (EGF) is a cytokine that comprises 53 amino acids (6.2 kDa) and is secreted by ectodermic cells, monocytes, kidneys, and duodenal glands (1). EGF stimulates growth of epidermal and epithelial cells. EGF and at least seven other growth factors and their transmembrane receptor kinases play important roles in cell proliferation, survival, adhesion, migration, and differentiation. The EGF receptor (EGFR) family consists of four transmembrane receptors: EGFR (HER1/erbB-1), HER2 (erbB-2/neu), HER3 (erbB-3), and HER4 (erbB-4) (2). HER1, HER3, and HER4 comprise three major functional domains: an extracellular ligand-binding domain, a hydrophobic transmembrane domain, and a cytoplasmic tyrosine kinase domain. No ligand has been clearly identified for HER2. However, HER2 can be activated as a result of ligand binding to other HER receptors with the formation of receptor homodimers and/or heterodimers (3). HER1 and HER2 are overexpressed on many solid tumor cells such as breast, non-small cell lung, head and neck, and colon cancers (4-6). The high levels of HER1 and HER2 expression on cancer cells are associated with a poor prognosis (7-10).">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK24582/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-micad-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/micad/Z-MaEEE-99mTc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK24582/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8CFBCC7D644C810000000000850073.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK24582/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/micad/TcTTA1/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">99mTc-Mercaptoacetyl-Glu-Glu-Glu-Affibody ZHER2:342</div><div class="j">Molecular Imaging and Contrast Agent Database (MICAD) [Internet]</div></div><div class="tail"><a href="/books/n/micad/Z-MAG3-99mTc/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK24582/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK24582/&text=99mTc-Mercaptoacetyl-Glu-Glu-Glu-Affibody%20ZHER2%3A342"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/micad/?report=reader">Title Information</a><a href="/books/n/micad/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK24582/?report=classic">Switch to classic view</a><a href="/books/NBK24582/pdf/Bookshelf_NBK24582.pdf">PDF (147K)</a><a href="/books/NBK24582/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK24582%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8CFBCC7D644C810000000000850073.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK24582_"><span class="title" itemprop="name"><sup>99m</sup>Tc-Mercaptoacetyl-Glu-Glu-Glu-Affibody Z<sub>HER2:342</sub></span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm"><sup>99m</sup>Tc-MaEEE-Z<sub>HER2:342</sub></div><p class="contribs">Leung K.</p><p class="fm-aai"><a href="#_NBK24582_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figZMaEEE99mTcT1"><a href="/books/NBK24582/table/Z-MaEEE-99mTc.T1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobZMaEEE99mTcT1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="Z-MaEEE-99mTc.T1"><a href="/books/NBK24582/table/Z-MaEEE-99mTc.T1/?report=objectonly" target="object" rid-ob="figobZMaEEE99mTcT1">Table</a></h4><p class="float-caption no_bottom_margin">
|
|
|
|
<i>In vitro</i>
|
|
|
|
|
|
Rodents
|
|
</p></div></div><div id="Z-MaEEE-99mTc.Background"><h2 id="_Z-MaEEE-99mTc_Background_">Background</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=HER2%20342%20" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Epidermal growth factor (EGF) is a cytokine that comprises 53 amino acids (6.2 kDa) and is secreted by ectodermic cells, monocytes, kidneys, and duodenal glands (<a class="bibr" href="#Z-MaEEE-99mTc.REF.1" rid="Z-MaEEE-99mTc.REF.1">1</a>). EGF stimulates growth of epidermal and epithelial cells. EGF and at least seven other growth factors and their transmembrane receptor kinases play important roles in cell proliferation, survival, adhesion, migration, and differentiation. The EGF receptor (EGFR) family consists of four transmembrane receptors: EGFR (HER1/erbB-1), HER2 (erbB-2/neu), HER3 (erbB-3), and HER4 (erbB-4) (<a class="bibr" href="#Z-MaEEE-99mTc.REF.2" rid="Z-MaEEE-99mTc.REF.2">2</a>). HER1, HER3, and HER4 comprise three major functional domains: an extracellular ligand-binding domain, a hydrophobic transmembrane domain, and a cytoplasmic tyrosine kinase domain. No ligand has been clearly identified for HER2. However, HER2 can be activated as a result of ligand binding to other HER receptors with the formation of receptor homodimers and/or heterodimers (<a class="bibr" href="#Z-MaEEE-99mTc.REF.3" rid="Z-MaEEE-99mTc.REF.3">3</a>). HER1 and HER2 are overexpressed on many solid tumor cells such as breast, non-small cell lung, head and neck, and colon cancers (<a class="bibr" href="#Z-MaEEE-99mTc.REF.4" rid="Z-MaEEE-99mTc.REF.4 Z-MaEEE-99mTc.REF.5 Z-MaEEE-99mTc.REF.6">4-6</a>). The high levels of HER1 and HER2 expression on cancer cells are associated with a poor prognosis (<a class="bibr" href="#Z-MaEEE-99mTc.REF.7" rid="Z-MaEEE-99mTc.REF.7 Z-MaEEE-99mTc.REF.8 Z-MaEEE-99mTc.REF.9 Z-MaEEE-99mTc.REF.10">7-10</a>).</p><p>Trastuzumab is a humanized IgG<sub>1</sub> monoclonal antibody (mAb) against the extracellular domain of recombinant HER2 with an affinity constant (<i>K</i><sub>d</sub>) of 0.1 nM (<a class="bibr" href="#Z-MaEEE-99mTc.REF.11" rid="Z-MaEEE-99mTc.REF.11">11</a>). Trastuzumab is approved for clinical use for anti-cancer therapies in both Europe and North America. <sup>111</sup>In-Trastuzumab, Cy5.5-trastuzumab, and <sup>68</sup>Ga-trastuzumab-F(ab')<sub>2</sub> eveloped for imaging human breast cancer (<a class="bibr" href="#Z-MaEEE-99mTc.REF.12" rid="Z-MaEEE-99mTc.REF.12 Z-MaEEE-99mTc.REF.13 Z-MaEEE-99mTc.REF.14 Z-MaEEE-99mTc.REF.15 Z-MaEEE-99mTc.REF.16">12-16</a>). However, the pharmacokinetics of the intact radiolabeled mAb, with high liver uptake and slow blood elimination, are generally not ideal for imaging. Smaller antibody fragments, such as Fab or F(ab´)<sub>2</sub>, have better imaging pharmacokinetics because they are rapidly excreted by the kidneys. A novel class of recombinant affinity ligands (Affibody molecules) for HER2 was constructed on the basis of the Z-domain residues (58 amino acids) from one of the IgG-binding domains of staphylococcal protein A (<a class="bibr" href="#Z-MaEEE-99mTc.REF.17" rid="Z-MaEEE-99mTc.REF.17">17</a>). Affibody molecules exhibit high binding affinity (<i>K</i><sub>d</sub>) to HER2 with <i>K</i><sub>d</sub> values <100 pM. Various radiolabeled Affibody molecules have been studied in terms of their ability to image HER2 in tumors [<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=affibody%20and%20HER2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]. Mercaptoacetyl-Gly-Gly-Gly (MAG3) was used a chelating linker for coupling <sup>99m</sup>Tc to Z<sub>HER2:342</sub> Affibody (<a class="bibr" href="#Z-MaEEE-99mTc.REF.18" rid="Z-MaEEE-99mTc.REF.18">18</a>). <sup>99m</sup>Tc-MAG3-Z<sub>HER2:342</sub> has been evaluated in nude mice bearing human colon adenocarcinoma tumors, resulting in high tumor/blood and tumor/muscle ratios. However, <sup>99m</sup>Tc-MAG3-Z<sub>HER2:342</sub> exhibited a high hepatobiliary clearance, which resulted in a high radioactivity in the intestines at 4 h after injection (<a class="bibr" href="#Z-MaEEE-99mTc.REF.19" rid="Z-MaEEE-99mTc.REF.19">19</a>). Therefore, glutamic acid was used as the chelating linker to decrease the lipophilicity of Z<sub>HER2:342</sub> Affibody to suppress hepatobiliary clearance (<a class="bibr" href="#Z-MaEEE-99mTc.REF.20" rid="Z-MaEEE-99mTc.REF.20">20</a>). <sup>99m</sup>Tc-Mercaptoacetyl-Glu-Glu-Glu-Affibody Z<sub>HER2:342</sub> (<sup>99m</sup>Tc-MaEEE-Z<sub>HER2:342</sub>) was found to a have favorable biodistribution in nude mice bearing SKOV-3 tumors, resulting in a 3-fold lower hepatobiliary clearance than <sup>99m</sup>Tc-MAG3-Z<sub>HER2:342</sub>.</p></div><div id="Z-MaEEE-99mTc.Synthesis"><h2 id="_Z-MaEEE-99mTc_Synthesis_">Synthesis</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=HER2%20342%20and%20synthesis" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Z<sub>HER2:342</sub> Affibody was prepared by standard solid phase peptide synthesis. MaEEE-Z<sub>HER2:342</sub> was prepared by addition of MaEEE to the N-terminal of the Z-Affibody (<a class="bibr" href="#Z-MaEEE-99mTc.REF.20" rid="Z-MaEEE-99mTc.REF.20">20</a>). <sup>99m</sup>Tc as pertechnetate was added to a solution of MaEEE-Z<sub>HER2:342</sub> containing SnCl<sub>2</sub>. The mixture was incubated for 60 min at room temperature. The labeling efficiency of <sup>99m</sup>Tc incorporation was 90 ± 2% with >98% purity. <sup>99m</sup>Tc- MaEEE-Z<sub>HER2:342</sub> was purified by size-exclusion chromatography. Specific activities of the preparations were not reported. <sup>99m</sup>Tc-MaEEE-Z<sub>HER2:342</sub> was found to be stable after incubation in murine blood plasma (>99%) at 37°C for 1 h or solution containing 300-fold excess cysteine (93 ± 3%) at 37°C for 2 h.</p></div><div id="Z-MaEEE-99mTc.In_Vitro_Studies_Tes"><h2 id="_Z-MaEEE-99mTc_In_Vitro_Studies_Tes_"><i>In Vitro</i> Studies: Testing in Cells and Tissues</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=HER2%20342%20and%20in%20vitro" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Tran et al. (<a class="bibr" href="#Z-MaEEE-99mTc.REF.20" rid="Z-MaEEE-99mTc.REF.20">20</a>) performed binding experiments with MaEEE-Z<sub>HER2:342</sub> with use of a Biacore sensor chip immobilized with extracellular domain of HER2 protein. The <i>K</i><sub>d</sub> values were 410 and 80 pM for MaEEE-Z<sub>HER2:342</sub> and Z<sub>HER2:342</sub>, respectively. Hence, the binding affinity of the synthetic Affibody molecule MaEEE-Z<sub>HER2:342</sub> was 4.1-fold lower than the parent Affibody molecule Z<sub>HER2:342</sub>. <i>In vitro</i> binding specificity tests showed that binding of <sup>99m</sup>Tc-MaEEE-Z<sub>HER2:342</sub> to SKOV-3 cells expressing HER2 was receptor-mediated because saturation of receptors by preincubation with non-labeled Z<sub>HER2:342</sub> significantly decreased binding of <sup>99m</sup>Tc-MaEEE-Z<sub>HER2:342</sub>. The antigen binding capacity of <sup>99m</sup>Tc-MaEEE-Z<sub>HER2:342</sub> was 67%. The cell-bound radioactivity remained constant at ~70% of the initially bound activity for up to 24 h when the cells were incubated with <sup>99m</sup>Tc-MaEEE-Z<sub>HER2:342</sub>. In contrast, cells incubated with <sup>125</sup>I-Z<sub>HER2:342</sub> retained ~40% of the original cell-associated radioactivity.</p></div><div id="Z-MaEEE-99mTc.Animal_Studies"><h2 id="_Z-MaEEE-99mTc_Animal_Studies_">Animal Studies</h2><div id="Z-MaEEE-99mTc.Rodents"><h3>Rodents</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=HER2%20342%20and%20rodentia" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Tran et al. (<a class="bibr" href="#Z-MaEEE-99mTc.REF.20" rid="Z-MaEEE-99mTc.REF.20">20</a>) performed biodistribution studies of 0.1 MBq (2.7 μCi) <sup>99m</sup>Tc-MaEEE-Z<sub>HER2:342</sub> in nude mice (<i>n</i> = 4) bearing SKOV-3 xenografts. <sup>99m</sup>Tc-MaEEE-Z<sub>HER2:342</sub> (0.14 nmol) was injected s.c. to each mouse. The initial tracer accumulation in the SKOV-3 tumors was 9.1% injected dose per gram (ID/g) at 1 h, 7.9% ID/g at 4 h and 6.1% ID/g 6 h after injection. The radioactivity level in tumors was higher than in other organs and tissues except the kidneys (>30% ID/g). Blood levels were ~2% ID/g at 1 h, and 0.15% ID/g at 6 h. The biodistribution was characterized by quick clearance of radioactivity from blood and all organs and tissues. The radioactivity of intestine content was <3% ID/g at 6 h. Tumor/blood ratios were 6, 38, and 43 at 1, 4, and 6 h after injection, respectively. Pre-administration of Z<sub>HER2:342</sub> (83 nmol) decreased tumor accumulation from 7.9 ± 1.0 to 0.30 ± 0.07% ID/g (<i>P</i> <0.0001) at 4 h after injection. Biodistribution studies were also performed in normal NMRI mice (<i>n</i> = 4) without bearing any tumors at 4 h after injection. The results showed low accumulation in all organs and tissues except with 95% ID/g in the kidneys and ~3% ID in the intestines. Single-photon emission computed tomography (SPECT) analysis was performed in nude mice bearing the SKOV-3 tumors after i.v. injection of 3 MBq (81 μCi) <sup>99m</sup>Tc-MaEEE. Tumor/muscle ratios were 8, 19, and 35 at 1, 2, and 5 h, respectively. No other organs were visualized except the kidneys. In mice pretreated with Z<sub>HER2:342</sub>, the tumors could not be clearly visualized with <sup>99m</sup>Tc-MaEEE-Z<sub>HER2:342</sub>. Tumor/muscle ratio was 3.6.as measured at 5 h after injection.</p></div><div id="Z-MaEEE-99mTc.Other_NonPrimate_Mam"><h3>Other Non-Primate Mammals</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=HER2%20342%20and%20%28dog%20or%20pig%20or%20sheep%20or%20rabbit%29" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="Z-MaEEE-99mTc.NonHuman_Primates"><h3>Non-Human Primates</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=HER2%20342%20and%20%28primate%20not%20human%29" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div></div><div id="Z-MaEEE-99mTc.Human_Studies"><h2 id="_Z-MaEEE-99mTc_Human_Studies_">Human Studies</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=HER2%20342%20and%20human" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="Z-MaEEE-99mTc.References"><h2 id="_Z-MaEEE-99mTc_References_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.1">Carpenter G., Cohen S.
|
|
<em>Epidermal growth factor.</em>
|
|
<span><span class="ref-journal">J Biol Chem. </span>1990;<span class="ref-vol">265</span>(14):7709–12.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2186024" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2186024</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.2">Yarden Y.
|
|
<em>The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.</em>
|
|
<span><span class="ref-journal">Eur J Cancer. </span>2001;<span class="ref-vol">37</span> Suppl 4:S3–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11597398" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11597398</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.3">Rubin I., Yarden Y.
|
|
<em>The basic biology of HER2.</em>
|
|
<span><span class="ref-journal">Ann Oncol. </span>2001;<span class="ref-vol">12</span> Suppl 1:S3–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11521719" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11521719</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.4">Grunwald V., Hidalgo M.
|
|
<em>Developing inhibitors of the epidermal growth factor receptor for cancer treatment.</em>
|
|
<span><span class="ref-journal">J Natl Cancer Inst. </span>2003;<span class="ref-vol">95</span>(12):851–67.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12813169" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12813169</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.5">Mendelsohn J.
|
|
<em>Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents.</em>
|
|
<span><span class="ref-journal">J Steroid Biochem Mol Biol. </span>1990;<span class="ref-vol">37</span>(6):889–92.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2285602" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2285602</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.6">Yasui W., Sumiyoshi H., Hata J., Kameda T., Ochiai A., Ito H., Tahara E.
|
|
<em>Expression of epidermal growth factor receptor in human gastric and colonic carcinomas.</em>
|
|
<span><span class="ref-journal">Cancer Res. </span>1988;<span class="ref-vol">48</span>(1):137–41.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2446740" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2446740</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.7">Ang K.K., Berkey B.A., Tu X., Zhang H.Z., Katz R., Hammond E.H., Fu K.K., Milas L.
|
|
<em>Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.</em>
|
|
<span><span class="ref-journal">Cancer Res. </span>2002;<span class="ref-vol">62</span>(24):7350–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12499279" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12499279</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.8">Costa S., Stamm H., Almendral A., Ludwig H., Wyss R., Fabbro D., Ernst A., Takahashi A., Eppenberger U.
|
|
<em>Predictive value of EGF receptor in breast cancer.</em>
|
|
<span><span class="ref-journal">Lancet. </span>1988;<span class="ref-vol">2</span>(8622):1258.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2903994" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2903994</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.9">Ethier S.P.
|
|
<em>Growth factor synthesis and human breast cancer progression.</em>
|
|
<span><span class="ref-journal">J Natl Cancer Inst. </span>1995;<span class="ref-vol">87</span>(13):964–73.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7629883" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7629883</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.10">Yarden Y.
|
|
<em>Biology of HER2 and its importance in breast cancer.</em>
|
|
<span><span class="ref-journal">Oncology. </span>2001;<span class="ref-vol">61</span> Suppl 2:1–13.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11694782" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11694782</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.11">Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., Shepard H.M.
|
|
<em>Humanization of an anti-p185HER2 antibody for human cancer therapy.</em>
|
|
<span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1992;<span class="ref-vol">89</span>(10):4285–9.</span> [<a href="/pmc/articles/PMC49066/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC49066</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1350088" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1350088</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.12">Perik P.J., Lub-De Hooge M.N., Gietema J.A., van der Graaf W.T., de Korte M.A., Jonkman S., Kosterink J.G., van Veldhuisen D.J., Sleijfer D.T., Jager P.L., de Vries E.G.
|
|
<em>Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.</em>
|
|
<span><span class="ref-journal">J Clin Oncol. </span>2006;<span class="ref-vol">24</span>(15):2276–82.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16710024" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16710024</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.13">Lub-de Hooge M.N., Kosterink J.G., Perik P.J., Nijnuis H., Tran L., Bart J., Suurmeijer A.J., de Jong S., Jager P.L., de Vries E.G.
|
|
<em>Preclinical characterisation of 111In-DTPA-trastuzumab.</em>
|
|
<span><span class="ref-journal">Br J Pharmacol. </span>2004;<span class="ref-vol">143</span>(1):99–106.</span> [<a href="/pmc/articles/PMC1575276/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1575276</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15289297" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15289297</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.14">Garmestani K., Milenic D.E., Plascjak P.S., Brechbiel M.W.
|
|
<em>A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin.</em>
|
|
<span><span class="ref-journal">Nucl Med Biol. </span>2002;<span class="ref-vol">29</span>(5):599–606.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12088731" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12088731</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>15.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.15">Smith-Jones P.M., Solit D., Afroze F., Rosen N., Larson S.M.
|
|
<em>Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.</em>
|
|
<span><span class="ref-journal">J Nucl Med. </span>2006;<span class="ref-vol">47</span>(5):793–6.</span> [<a href="/pmc/articles/PMC3193602/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3193602</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16644749" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16644749</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>16.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.16">Smith-Jones P.M., Solit D.B., Akhurst T., Afroze F., Rosen N., Larson S.M.
|
|
<em>Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.</em>
|
|
<span><span class="ref-journal">Nat Biotechnol. </span>2004;<span class="ref-vol">22</span>(6):701–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15133471" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15133471</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>17.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.17">Wikman M., Steffen A.C., Gunneriusson E., Tolmachev V., Adams G.P., Carlsson J., Stahl S.
|
|
<em>Selection and characterization of HER2/neu-binding affibody ligands.</em>
|
|
<span><span class="ref-journal">Protein Eng Des Sel. </span>2004;<span class="ref-vol">17</span>(5):455–62.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15208403" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15208403</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>18.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.18">Engfeldt, T., A. Orlova, T. Tran, A. Bruskin, C. Widstrom, A.E. Karlstrom, and V. Tolmachev, <em>Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the (99m)Tc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.</em> Eur J Nucl Med Mol Imaging, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/17146656" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17146656</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>19.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.19">Tran T., Engfeldt T., Orlova A., Widstrom C., Bruskin A., Tolmachev V., Karlstrom A.E.
|
|
<em>In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules.</em>
|
|
<span><span class="ref-journal">Bioconjug Chem. </span>2007;<span class="ref-vol">18</span>(2):549–58.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17330952" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17330952</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>20.</dt><dd><div class="bk_ref" id="Z-MaEEE-99mTc.REF.20">Tran T., Engfeldt T., Orlova A., Sandstrom M., Feldwisch J., Abrahmsen L., Wennborg A., Tolmachev V., Karlstrom A.E.
|
|
<em>(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.</em>
|
|
<span><span class="ref-journal">Bioconjug Chem. </span>2007;<span class="ref-vol">18</span>(6):1956–64.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17944527" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17944527</span></a>]</div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK24582_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Kam Leung</span>, PhD<div class="affiliation small">National Center for Biotechnology Information, NLM, NIH<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.mln.ibcn@DACIM" class="oemail">vog.hin.mln.ibcn@DACIM</a></div></div><div class="small">Corresponding author.</div></div><h3>Publication History</h3><p class="small">Created: <span itemprop="datePublished">March 16, 2008</span>; Last Update: <span itemprop="dateModified">April 7, 2008</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="http://www.ncbi.nlm.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Center for Biotechnology Information (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Leung K. 99mTc-Mercaptoacetyl-Glu-Glu-Glu-Affibody ZHER2:342. 2008 Mar 16 [Updated 2008 Apr 7]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/micad/TcTTA1/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/micad/Z-MAG3-99mTc/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobZMaEEE99mTcT1"><div id="Z-MaEEE-99mTc.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK24582/table/Z-MaEEE-99mTc.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Z-MaEEE-99mTc.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Chemical name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>99m</sup>Tc-Mercaptoacetyl-Glu-Glu-Glu-Affibody Z<sub>HER2:342</sub></td><td rowspan="9" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Abbreviated name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>99m</sup>Tc-MaEEE-Z<sub>HER2:342</sub></td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Synonym:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Agent category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Antibody fragment, Affibody</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EGF HER2 receptor</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Receptor</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Method of detection:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPECT, gamma planar</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Source of signal:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>99m</sup>Tc</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Activation:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Studies:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" />
|
|
<i>In vitro</i>
|
|
|
|
</div></li><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Rodents
|
|
</div></li></ul>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Click on <a href="/entrez/viewer.fcgi?db=protein&val=54792098" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">protein</a>, <a href="/entrez/viewer.fcgi?val=NM_201282.1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">nucleotide</a> (RefSeq), and <a href="/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=1956" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">gene</a> for more information about HER2.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|